Stockreport

BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF randomized 2:1 to infigratinib or placebo over 52 weeks and annualized height velocity as the primary endpoint. Infigratinib is an oral FGFR1/2/3 inhibitor targeting o [Read more]